Views published in Economic Times regarding Monsanto’s patent rejection order passed by Intellectual Property Appellate Board (IPAB).
Biosimilars are generic versions of biologics, medicinal products with active drug component being made (or derived) from a living organism. It is complicated and cost intensive to manufacture biologics, and hence…
BioSpectrum Asia — Debate over compulsory licensing of Bayer’s Nexavar
Full Article: India allows compulsory licensing of Bayer’s Nexavar
Full Article: Patent Opposition in India: Recent Trends
Overview of patent opposition in India, the two-stage patent opposition process and how it affects the industry, as the patent applicants are now vulnerable to…
Global Legal Post Publication
Before US visit, PM Modi announced to resolve one the most crucial issues daunting the Indian Patent Office, i.e. clearing the huge backlog.
By 2020, according to Frost & Sullivan, healthcare expenditure in the APAC will increase 151 percent over 2010 figure, to $2927 billion at a compound annual growth rate of 9.2 percent.
Originally published on LinkedIn at: http://www.linkedin.com/today/post/article/20140629171748-78097585-beginner-s-guide-to-pharmaceutical-patent-protections…